跳至主要内容
临床试验/EUCTR2012-002785-12-IT
EUCTR2012-002785-12-IT进行中(未招募)不适用

A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients withschizophrenia

H. Lundbeck A/S0 个研究点目标入组 286 人开始时间: 2013年2月21日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
286

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • ? The patient has schizophrenia, diagnosed according to DSM-IV TR™.
  • ? The patient is a man or woman, aged =18 and =60 years.
  • ? The patient has been prescribed oral antipsychotic treatment for the full 3 months prior to the Screening Visit.
  • ? The patient has CGI-S score =3 (mildly ill) and =5 (markedly ill) at the Screening and Baseline Visits .
  • ? The patient is in need of a change in the current antipsychotic treatment and in the judgement of the
  • investigator the patient would benefit from an extended treatment with a once-monthly formulation, including
  • but not limited to any of the following reasons:
  • - lack of adequate response to his or her current antipsychotic medication,
  • - poor tolerability to his or her current antipsychotic medication,
  • - lack of adherence to his or her current antipsychotic medication.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 286
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • The patient has any current psychiatric disorder or Axis I disorder (DSM-IV™ criteria) other than
  • schizophrenia established as the primary diagnosis.
  • ? The patient has a substance use disorder (except nicotine) which according to the investigator’s judgment may
  • compromise the patient’s ability to comply with the study procedures, or preclude the benefits of the study
  • medication.
  • ? The patient in the investigator’s judgment has shown significant intolerance and/or lack of efficacy to oral
  • aripiprazole, paliperidone or risperidone, in a manner that would preclude benefiting from the study
  • medication if randomised to the same IMP during the study.
  • ? The patient has been treated with a long-acting injectable atypical antipsychotic drugs such as olanzapine,
  • paliperidone, or aripiprazole <6 months prior to the Screening Visit.
  • ? The patient is experiencing acute exacerbation of psychotic symptoms at the Screening Visit or between the
  • Screening and Baseline Visits.
  • ? The patient is hospitalised at the time of the Screening Visit for a period longer than 3 months.
  • ? The patient is considered resistant to antipsychotic treatment according to the investigator’s judgement, or has
  • a history of failure to respond to clozapine treatment, or a history of responding only to clozapine treatment.
  • ? The patient is at significant risk of harming himself/herself or others according to the investigator’s judgement
  • or as indicated by an answer of yes” to questions 4 or 5 on the C-SSRS at the Screening or Baseline Visit.

研究者

相似试验

Aripiprazole Once-monthly Versus Paliperidone... | 临床试验